All News
CV risk factors not equal when considering magnitude of risk
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
Read Article
Can we stop RA before it happens?
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals.
Read Article
Is Pain Control by Cannabis an Option?
An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation.
Read Article
Topical therapies take centre stage
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium.
Read Article
Video: Residual Pain in RA
Dr. Maxime Dougados discusses OP0052 at #EULAR2022.
https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW
Links:
Dr. John Cush RheumNow ( View Tweet)
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is not currently approved for B-cell NHL, B-cell leukemia, MPA, or GPA. or pemphigus vulgaris (RTX is an orphan drug) https://t.co/Htk0xBx63X https://t.co/ep1L3YO9hl
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Major Consequences of Depression In RA
https://t.co/aVzIHDiRZ4 https://t.co/86RLXJKb64
Links:
Dr. John Cush RheumNow ( View Tweet)
VIDEO: No Glory in GLORIA
Dr. Richard Conway discusses abstract OP0263 presented at #EULAR2022.
https://t.co/tlsTPztYqY https://t.co/5dOma69vLZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Let’s Talk about Sex and Autoimmune Disease
Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022.
https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Demystifying Synovial Tissue Biology
Dr. Aurelie Najm ( @AurelieRheumo) discusses abstracts OP0084 and OP0085 presented at #EULAR2022.
https://t.co/LNfFmxiE8O https://t.co/aiLvdtxYRB
Links:
Dr. John Cush RheumNow ( View Tweet)
VIDEO: Golden Window in Pre-RA
Dr. Richard Conway ( @RichardPAConway) discusses abstract OP0070 presented at #EULAR2022.
https://t.co/VoVo4TTgvO https://t.co/7NrZqJlwjo
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR recommendations for management of #RheumatoidArthritis
6️⃣Glucocorticoids should be tapered & discontinued as soon as clinically feasible
8️⃣JAKi can be used but consider risk factors
via Prof Smolen #EULAR2022 https://t.co/7cocPSpgkH
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej
Janet Pope Janetbirdope ( View Tweet)
WATCH: Not Your Kind of RA
Dr. David Liew discusses abstract OP0035 presented at #EULAR2022
Background: It has been suggested that rheumatoid arthritis (RA) starts at a younger age in cities with a lower latitude (closer to both sides of the equator).
https://t.co/0l8b95emkn https://t.co/2leBR1nOBJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Sing an ARIAA! #Bestinclass Rx of arthralgia w +MRI showed delay of #rheumatoid arthritis w #Abatacept vs #placebo. NNT to prevent 1 RA [is 8 w Rx for 1 yr & then d/c-Yrs ago #MTX delayed onset of RA but benefit waned after d/c Rx. Both ?RA spectrum POS0531 @RheumNow #EULAR2022
Janet Pope Janetbirdope ( View Tweet)
72% of you would treat some high-risk subclinical arthralgias with MTX
and Marta Mosca, in the #EULAR2022 highlights, broadly agrees
OP0070 Leiden data showed better function and presenteeism. And that’s a win in my book
@RheumNow https://t.co/BqTLy4HBWR https://t.co/cwzJkH0f71
David Liew drdavidliew ( View Tweet)
#OP0004 #EULAR2022 In line with EULAR President’s preech to go Digital, Prof Mosca highlighted a study which showed assessment of joints in RA could be done by taking photos and analysed their dorsal skin folds using convolutional neural network @RheumNow https://t.co/h03mieTcQt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change.
In the 2022 version:
JAKi now separate sentence following bDMARDs, with proviso to mention risk.
Sometimes guidelines have to tell us what we’ve all inevitably been expecting
#EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
David Liew drdavidliew ( View Tweet)
#highlight n•1 💫
The presence of specific peripheral blood T cell sub-populations associated w/ disease flares
in RA pts in remission after cs or bioDMARDs tapering or cessation
identified in 2 different abstracts
OP0011 and OP0074
@RheumNow #EULAR2022 https://t.co/SO2AgtkyTP
Aurelie Najm AurelieRheumo ( View Tweet)
